The FDA has recalled about 600,000 bottles of Ramipril, a common blood pressure medication, due to contamination concerns tied to an unregulated supplier in India. The recall involves 2.5 mg, 5 mg, and 10 mg doses distributed across the U.S. Classified as a Class 2 recall, the contamination might cause temporary or medically reversible health effects, though no serious incidents have been reported.

Ramipril is vital for managing hypertension and reducing risks of heart attacks, strokes, and kidney issues, so the recall has raised concern among patients and healthcare providers. This case highlights the need for stricter oversight of global pharmaceutical supply chains, especially for overseas manufacturers.

Patients are urged not to stop taking Ramipril without medical advice but should check with their pharmacy or the FDA database to see if their medication is affected. Overall, the recall stresses the importance of rigorous quality control in drug manufacturing.